BD ProbeTec™ Herpes Simplex Viruses Qx Amplified DNA Assays for the BD Viper™ System with XTR™ Technology
First fully automated, FDA-cleared molecular assays for HSV1 and HSV2
Where Sensitivity Advances Clinical Performance
What's the most critical factor facing clinical laboratories today?
Achieving optimal performance means delivering results against a backdrop of unprecedented challenges, including:
What do these challenges mean when it comes to clinical testing for diseases caused by herpes viruses?
The rising prevalence of Herpes Simplex virus type 1 (HSV1) and Herpes Simplex virus type 2 (HSV2) and the need for a better understanding of underlying health risks are increasing the demand for more stringent and better overall testing.
Yet research data suggests that many clinical laboratories continue to use traditional culture-based tests to diagnose herpes virus infections, which can result in significant false negative rates and missing up to 50 percent of true positive cases1. In addition, many clinicians and laboratories do not distinguish between HSV1 and HSV2 - meaning patient treatment plans and patient outcomes can be negatively affected.
These limitations can lead to retesting, which is time-consuming and expensive, resulting in increased frustration and distrust from doctors and patients who require fast, accurate results.
In the end, what's the real cost of outdated technology to you, the physicians and the patients you serve?
For patients, continuing to test for HSV using traditional culturing methods can mean delayed treatment - or worse, the wrong treatment altogether.
For the physician, viral culture results can be affected by improper temperature requirements during transport, leading to false negative results. If the patient had a late-stage lesion that has healed, collecting another specimen may not be possible.
For your business, less efficient testing methods result in decreased productivity and, ultimately, increased cost. Not only are live culture tests costly in terms of price per test and additional labor, but also due to the requirement to transport viable organisms in a strict, secure manner. Together, these inefficiencies translate into a quantifiable negative impact on your laboratory's bottom line.
How can you improve your HSV testing performance and achieve positive economic impact?
As the first fully automated, FDA-cleared molecular assays for HSV1 and HSV2, the BD ProbeTec™ Herpes Simplex Viruses (HSV 1 & 2) Qx Amplified DNA Assays deliver a complete solution for the clinical laboratory wanting performance plus profitability.
The BD ProbeTec Herpes Simplex Viruses Qx Amplified DNA Assays, when run on the BD Viper™ System in Extracted Mode, use Strand Displacement Amplification technology to qualitatively detect and differentiate HSV1 and HSV2 DNA in clinician-collected external anogenital lesion specimens as an aid in the diagnosis of herpes infection.
With this technology you can improve your laboratory's overall competitiveness by providing higher quality results for improved patient care, better lab efficiency and increased standardization. You'll also see a greater return on your investment through:
The BD ProbeTec™ Herpes Simplex Viruses (HSV 1 & 2) Qx Amplified DNA Assays run on the BD Viper™ System with XTR™ Technology, are designed to give clinicians better tools to manage patients who may be suffering from a variety of the most pressing sexually transmitted infections.
The BD ProbeTec Herpes Simplex Viruses (HSV1 & 2) Qx Amplified DNA Assays run on the BD Viper System with XTR Technology deliver:
Note: The BD ProbeTec HSV Qx Assays are not FDA cleared for use with cerebrospinal fluid (CSF) or any lesions other than anogenital lesions. The assays are not intended to be used for prenatal screening or for individuals under the age of 17 years.
1 N. Nguyen, C.N. Burkhart, C.G. Burkhart. 2010. Identifying potential pitfalls in conventional herpes simplex virus management. Int. J. Dermatol. 49: 987-993.
2 BD ProbeTec™ Herpes Simplex Viruses (HSV 1 & 2) Qx Amplified DNA Assays Package Insert, 8086121